244 related articles for article (PubMed ID: 30307530)
1. Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials.
Sen S; Carmagnani Pestana R; Hess K; Viola GM; Subbiah V
Ann Oncol; 2018 Dec; 29(12):2396-2398. PubMed ID: 30307530
[No Abstract] [Full Text] [Related]
2. Immune checkpoint inhibitors.
Hui E
J Cell Biol; 2019 Mar; 218(3):740-741. PubMed ID: 30760493
[TBL] [Abstract][Full Text] [Related]
3. Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy.
Bazhin AV; Amedei A; Karakhanova S
Front Immunol; 2018; 9():2878. PubMed ID: 30568661
[No Abstract] [Full Text] [Related]
4. Checkpoint Inhibitors: Conquering Cancer with a Little (T)-Help from Our Microbial Friends.
Asmar N; Ibrahim T; Rey JF
Dig Dis Sci; 2018 Sep; 63(9):2177-2179. PubMed ID: 29982987
[No Abstract] [Full Text] [Related]
5. Adverse events associated with immune checkpoint inhibitor treatment for cancer.
Esfahani K; Meti N; Miller WH; Hudson M
CMAJ; 2019 Jan; 191(2):E40-E46. PubMed ID: 30642824
[No Abstract] [Full Text] [Related]
6. Influence of Gastrointestinal Flora in the Treatment of Cancer with Immune Checkpoint Inhibitors.
Mendoza L
Klin Onkol; 2018; 31(6):465-467. PubMed ID: 30545227
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of immune checkpoint blockade for brain metastases.
Harary M; Reardon DA; Iorgulescu JB
CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
[No Abstract] [Full Text] [Related]
8. Checkpoint blockade after kidney transplantation.
Lesouhaitier M; Dudreuilh C; Tamain M; Kanaan N; Bailly E; Legoupil D; Deltombe C; Perrin P; Manson G; Vigneau C; Houot R
Eur J Cancer; 2018 Jun; 96():111-114. PubMed ID: 29705511
[No Abstract] [Full Text] [Related]
9. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
Anderson R; Theron AJ; Rapoport BL
Front Immunol; 2019; 10():2254. PubMed ID: 31616428
[TBL] [Abstract][Full Text] [Related]
10. Dissecting the mechanisms of immune checkpoint therapy.
Sharma P; Allison JP
Nat Rev Immunol; 2020 Feb; 20(2):75-76. PubMed ID: 31925406
[No Abstract] [Full Text] [Related]
11. The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment.
O'Donnell JS; Hoefsmit EP; Smyth MJ; Blank CU; Teng MWL
Clin Cancer Res; 2019 Oct; 25(19):5743-5751. PubMed ID: 31040150
[TBL] [Abstract][Full Text] [Related]
12. Atypical autoimmune adverse effects with checkpoint blockade therapies.
Friedman CF; Snyder A
Ann Oncol; 2017 Feb; 28(2):206-207. PubMed ID: 27993802
[No Abstract] [Full Text] [Related]
13. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
Chang X; Lu X; Guo J; Teng GJ
Cancer Treat Rev; 2019 Mar; 74():49-60. PubMed ID: 30831375
[TBL] [Abstract][Full Text] [Related]
14. The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy.
Puza CJ; Bressler ES; Terando AM; Howard JH; Brown MC; Hanks B; Salama AKS; Beasley GM
J Surg Res; 2019 Apr; 236():209-215. PubMed ID: 30694757
[TBL] [Abstract][Full Text] [Related]
15. [The "immune checkpoints", how does it work].
Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H
Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies.
Desnoyer A; Broutin S; Delahousse J; Maritaz C; Blondel L; Mir O; Chaput N; Paci A
Eur J Cancer; 2020 Mar; 128():119-128. PubMed ID: 32037060
[TBL] [Abstract][Full Text] [Related]
17. Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors.
Kennedy LC; Bhatia S; Thompson JA; Grivas P
J Natl Compr Canc Netw; 2019 Jun; 17(6):750-757. PubMed ID: 31200356
[TBL] [Abstract][Full Text] [Related]
18. Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors).
Wu Y; Ju Q; Jia K; Yu J; Shi H; Wu H; Jiang M
Int J Cancer; 2018 Jul; 143(1):45-51. PubMed ID: 29424425
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor-induced sarcoidosis-like granulomas.
Rambhia PH; Reichert B; Scott JF; Feneran AN; Kazakov JA; Honda K; Koon H; Gerstenblith MR
Int J Clin Oncol; 2019 Oct; 24(10):1171-1181. PubMed ID: 31321613
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials.
Nie RC; Chen FP; Yuan SQ; Luo YS; Chen S; Chen YM; Chen XJ; Chen YB; Li YF; Zhou ZW
Eur J Cancer; 2019 Jan; 106():1-11. PubMed ID: 30453169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
